Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
March 31, 2015 at 08:59 AM EDT
Ocata Therapeutics, Inc. ("Ocata"; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the company ...